# Laboratory Characterization of Co-Infections in Individuals Infected with HHV-8

## TL;DR

This study explores co-infections in people with HHV-8, showing that many have additional viral, bacterial, and other infections, which highlights the need for thorough testing.

## Contribution

The study identifies patterns of co-infections in HHV-8-infected individuals and emphasizes the importance of comprehensive diagnostics.

## Key findings

- 92% of patients were co-infected with HIV and Epstein-Barr Virus.
- Bacterial co-infections were more common in Kaposi sarcoma patients than in those with MCD.
- 43 co-infections were identified, including viral, bacterial, parasitic, and fungal pathogens.

## Abstract

HHV-8 infection can be asymptomatic in immunocompetent individuals but poses significant risks in immunocompromised patients. As an oncovirus, it can lead to Kaposi sarcoma (KS), primary effusion lymphoma, and multicentric Castleman disease (MCD). While the association between HHV-8 and HIV is well-established, other co-infections remain underexplored due to the low incidence of HHV-8 infections. This retrospective, observational study examines twelve individuals infected with HHV-8 over seven years, focusing on patterns of co-infection and the diagnostic need for clinical management. The average age for all patients included in this study was 56 years, and a majority were male (92%). Over a majority presented with fever, night sweats, fatigue, dyspnea, and lymphadenopathy. MCD was the most common diagnosis (42%), followed by KS in the context of MCD (33%). Nearly all patients (92%) were HIV and Epstein-Barr Virus positive, with a total of 43 co-infections identified, including viral (72%), bacterial (16%), parasitic (7%), and fungal (5%) pathogens. Bacterial co-infections were more prevalent in patients diagnosed with KS than in those with MCD (p = 0.02). Given the burden of various co-infections, our findings highlight the need for comprehensive diagnostic testing to guide optimal clinical management and improve patient outcomes.